Intranasal and intramuscular H5-Matrix-M nanoparticle vaccines protects against highly pathogenic H5N1 influenza virus in mice

Competing interests

The Boon laboratory received funding support from Novavax Inc. to conduct this study. A.C.M.B., K.P., T.L.D., and L.C.H. have no financial competing interest. Novavax authors are current or former employees of Novavax, Inc., a for-profit organization, who own stock or hold stock options. A.C.M.B. is on the editorial board of Journal of Virology. A.C.M.B. was not involved in the journal’s review of, or decisions related to, this manuscript.

Comments (0)

No login
gif